NLS Pharmaceutics Launches Preclinical Program for Mazindol ER
NLS Pharmaceutics Ltd. (NASDAQ: NLSP) is initiating a groundbreaking preclinical program for Mazindol ER, aimed at treating fentanyl dependence, an escalating public health crisis. In a recent report, the CDC highlighted a harrowing statistic of 105,007 drug overdose deaths, with synthetic opioids like fentanyl being involved in a staggering 90% of these incidents.
Mazindol ER: A Promising Non-Opioid Alternative
Mazindol ER is recognized for its potential as a non-opioid alternative, strategically targeting the neurochemical imbalances caused by fentanyl addiction. This extended-release formulation is protected under patents that extend beyond September 2038, giving it a competitive edge in the biopharmaceutical landscape.
The Critical Need for Innovative Treatments
As fentanyl dependence escalates, the need for innovative treatment approaches is more urgent than ever. Alex Zwyer, Chief Executive Officer of NLS, emphasized the company's commitment to exploring the unique pharmacological effects of Mazindol. This therapy aims to effectively target multiple neurotransmitter systems, which play significant roles in opioid addiction.
Highlights of the Preclinical Study
The preclinical study, dubbed Study KO-943, is set to evaluate the following key points:
- Safety and efficacy of Mazindol ER in models of fentanyl dependence.
- Pharmacokinetics and pharmacodynamics in opioid-exposed subjects.
- Impact on cravings, withdrawal symptoms, and cognitive performance.
This comprehensive study will be conducted over the next 12 to 18 months, with hopes of successful outcomes leading to regulatory pathways for clinical development.
Scientific Insights into Mazindol ER
Mazindol distinguishes itself as a tetracyclic compound, exhibiting a unique action on several neurotransmitter pathways. Its multi-dimensional mechanism addresses cravings and withdrawal symptoms through:
- 5-HT1A receptor modulation, which can help regulate mood and anxiety.
- Partial modulation of mu-opioid receptors to alleviate cravings without reinforcing addiction.
- Activity on orexin-2 receptors to aid in regulating sleep-wake cycles disrupted by opioid withdrawal.
Expanding Horizons: Future Developments
In addition to advancing the Mazindol ER program, NLS is developing other innovative pipeline candidates. These include:
- NLS-4 (Lauflumide): A promising agent designed to enhance wakefulness.
- NLS-11 (Benedin): Targeted for circadian rhythm modulation with applications in various fields.
- NLS-3 (Levophacetoperane SR): A potential breakthrough in treating ADHD and Autism Spectrum Disorders.
About NLS Pharmaceutics Ltd.
NLS Pharmaceutics is a clinical-stage biopharmaceutical firm dedicated to discovering and developing transformative therapies for individuals with complex central nervous system disorders. With headquarters in Switzerland, NLS is led by an experienced team capable of advancing its promising product candidates. The company focuses on unmet medical needs and aims to enhance treatment options across various indications.
About Kadimastem
Kadimastem specializes in clinical-stage cell therapy development, leveraging its platform for creating functional cells from human embryonic stem cells. The company has made significant strides in therapies for ALS and diabetes, contributing valuable advancements to the medical field.
Frequently Asked Questions
What is the aim of the preclinical program for Mazindol ER?
The program aims to assess the safety and effectiveness of Mazindol ER in treating fentanyl dependence.
When is the study expected to be completed?
The study is anticipated to conclude within 12 to 18 months.
What makes Mazindol ER a unique treatment option?
Mazindol ER is characterized by its multi-target mechanism, designed to alleviate cravings and withdrawal symptoms without reinforcing addiction.
How does NLS Pharmaceutics support its developments?
NLS Pharmaceutics collaborates with experts to discover innovative therapies tailored for severe health needs.
Are there other pipeline candidates in development?
Yes, NLS is also developing additional candidates, aiming to broaden treatment possibilities for various disorders.
